You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Preparation and Characterization of 2nd Generation HIV-1 Maturation Inhibitor Dru
SBC: DFH Pharma, Inc Topic: NIAIDDESCRIPTION (provided by applicant): Despite advances in the development of HIV drugs there remains a need for new therapies. Toxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antivirals. Maturation inhibitors (MIs) represent one such class of HIV therapies. HIV maturation inhibitors block virus r ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk
SBC: ZENAGENE, INC. Topic: NCIDESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy
SBC: FOR-ROBIN, INC. Topic: NCIDESCRIPTION (provided by applicant): This proposal aims to develop a novel, highly-specific targeted therapy for treatment of breast cancer. The long-term objective is to convert the proprietary intellectual property, the mouse monoclonal antibody (McAb)JAA-F11, which targets the pancarcinoma Thomsen-Friedenreich antigen (TF-Ag) to a humanized form for use as an adjunct with conventional therapy ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Targeted Polymer Micelles for Treatment of Metastatic Melanoma
SBC: INTEZYNE TECHNOLOGIES, INC. Topic: NCIDESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors
SBC: SIXONE SOLUTIONS, LLC Topic: NCIDESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Mobile App Targeting Meth Use, HIV Sex Risks and ART Adherence for Gay/Bisexual Men
SBC: COG ANALYTICS, LLC Topic: NIDADESCRIPTION (provided by applicant): Methamphetamine use among gay and bisexually identified men (GBM) and other men who have sex with men (MSM) is strongly associated with HIV infection due to the concomitant high-risk sexual behaviors that often occur while using the drug. As a result, HIV prevalence is significantly higher among MSM that report frequent use of methamphetamine and highest among ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Live-Cell Fluorescence Lifetime FRET Assays for HTS
SBC: Fluorescence Innovations, Inc. Topic: NIDADESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Communication in Infants and Social Screener: The CISS
SBC: PAUL H BROOKES PUBLISHING CO., INC. Topic: NIDCDDESCRIPTION (provided by applicant): Effective early intervention depends on reliable screening of risk for communication impairments as soon as possible. Established infant communication risk factors include poor attention, gestures, social connectedness,exploratory play, and speech. Although these risk factors can be detected by 12-18 mos. and reliably predict later language and social disorders ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Screens for Novel Agonists/Antagonists of Endocrine Fibroblast Growth Factors
SBC: AGAVE BIOSYSTEMS INC. Topic: NIDDKDESCRIPTION (provided by applicant): Agave BioSystems and Professor Makoto Kuro-o at the University of Texas Southwestern Medical Center are proposing a collaborative effort to screen for novel small molecules acting as agonists or antagonists of the Klotho and Klotho- dependent endocrine Fibroblast Growth Factors. The expected outcome of this Phase I effort will be the validation of a high-throug ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti
SBC: Theragnostic Technologies Inc. Topic: NIDDKAbstract This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure. Every year, in the US, approximately 20 million people are treated for mild to severe renal failure. A significant number of cases (greater than 50%) related to ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health